30-day FRN

Federal Register / Vol. 81, No. 185 / Friday, September 23, 2016 / Notices
should be directed to: Susan Ano, Ph.D.,
NINDS Technology Transfer, 31 Center
Drive, Suite 8A52, MS2540, Bethesda,
MD 20892; Telephone: (301) 435–5515;
Email: [email protected].
SUPPLEMENTARY INFORMATION:

[FR Doc. 2016–22897 Filed 9–22–16; 8:45 am]

This

sradovich on DSK3GMQ082PROD with NOTICES

invention discloses treating
neurodegenerative diseases by
administering cyclin dependent kinase
5 (Cdk5) inhibitory peptides derived
from P35, the activator of Cdk5.
Abnormally hyperactive Cdk5 has been
shown to be associated with a variety of
neurodegenerative disorders. This
invention describes isolated peptide
fragments, pharmaceutical compositions
and methods for use of such for treating
subjects with a neurodegenerative
disease, such as Alzheimer’s disease
(AD), Amyotrophic Lateral Sclerosis
(ALS) and Parkinson’s disease (PD). An
inhibitory fragment, TFP5, disclosed in
this invention, has been shown to
ameliorate symptoms of AD in disease
animal models without any evidence of
toxicity. In particular, TFP5 treatment of
rat cortical neurons reduced
hyperactivation of Cdk5 upon neuronal
stress and insults. Following
intraperitoneal (ip) injection, TFP5 was
capable of crossing the blood-brain
barrier and localizing within the brain
where it was found to rescue memory
deficits and pathology in a double
transgenic mouse (APP/PS1) AD model.
The prospective start-up exclusive
license may be granted unless within
fifteen (15) days from the date of this
published notice, the NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the field of use filed in response to this
notice will be treated as objections to
the grant of the contemplated start-up
exclusive license. Comments and
objections submitted to this notice will
not be made available for public
inspection and, to the extent permitted
by law, will not be released under the
Freedom of Information Act, 5 U.S.C.
552.

VerDate Sep<11>2014

18:22 Sep 22, 2016

Jkt 238001

Dated: September 19, 2016.
Susan Ano,
Technology Development Coordinator,
NINDS Technology Transfer, National
Institutes of Health.
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Palliative Care:
Conversations Matter® Phase Two
Evaluation (National Institute of
Nursing Research)
National Institutes of Health,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:

In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below. This proposed
information collection was previously
published in the Federal Register on
July 12, 2016, page 45169 (81 FR 45169)
and allowed 60 days for public
comment. No public comments were
received. The purpose of this notice is
to allow an additional 30 days for public
comment.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30 days of the date of this
publication.
ADDRESSES: Written comments and/or
suggestions regarding the item(s)
contained in this notice, especially
regarding the estimated public burden
and associated response time, should be
directed to the: Office of Management
and Budget, Office of Regulatory Affairs,
[email protected] or by
fax to (202) 395–6974, Attention: Desk
Officer for NIH.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Ms. Diana
Finegold, Office of Communications and
Public Liaison, NINR, NIH, Building 31,
SUMMARY:

PO 00000

Frm 00042

Fmt 4703

Sfmt 4703

65663

Suite 5B03, 31 Center Drive, Bethesda,
MD 20892, or call non-toll-free number
(301) 496–0209, or Email your request,
including your address to:
[email protected].
SUPPLEMENTARY INFORMATION: The
National Institute of Nursing Research
(NINR), National Institutes of Health,
may not conduct or sponsor, and the
respondent is not required to respond
to, an information collection that has
been extended, revised, or implemented
on or after October 1, 1995, unless it
displays a currently valid OMB control
number.
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection: Palliative Care:
Conversations Matter® Phase Two
Evaluation, 0925–0683, National
Institute of Nursing Research (NINR),
National Institutes of Health (NIH).
Need and Use of Information
Collection: The NINR Palliative Care:
Conversations Matter® initiative, which
launched in FY 2014, is now in its
second phase. The first phase was
focused on providing materials and
tools to assist health care providers in
having sometimes difficult
conversations with children and
families about palliative care. The
second phase of the campaign, launched
in FY 2015, focuses on children,
parents, and families. The Palliative
Care: Conversations Matter® Phase Two
evaluation will assess the information
and materials being disseminated to
children, parents, and families. Survey
findings will help (1) determine if the
campaign is effective, relevant, and
useful to the families and caregivers of
children living with serious illnesses;
(2) to better understand the information
needs of families and caregivers to
inform future campaign efforts; and (3)
examine how effective the campaign
materials are in providing families and
caregivers with information on
palliative care.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
371 hours.

E:\FR\FM\23SEN1.SGM

23SEN1

65664

Federal Register / Vol. 81, No. 185 / Friday, September 23, 2016 / Notices
TABLE A–12–1—ESTIMATED ANNUALIZED BURDEN HOURS

Screener ...........
Main Survey ......

Parents and Caregivers ....................................................
Parents and Caregivers of Children with Serious Illnesses—Completes.

10,000
150

1
1

2/60
15/60

333
38

Total ...........

...........................................................................................

10,150

10,150

........................

371

[FR Doc. 2016–22998 Filed 9–22–16; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

sradovich on DSK3GMQ082PROD with NOTICES

Average
burden per
response
(in hours)

Type of
respondents

Dated: September 13, 2016.
Diana Finegold,
Project Clearance Liaison, NINR, NIH.

Name of Committee: National Cancer
Institute Initial Review Group; Subcommittee
I—Transition to Independence.
Date: October 18–19, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Ritz-Carlton Hotel at Pentagon City,
1250 South Hayes Street, Arlington, VA
22202.
Contact Person: Delia Tang, MD, Scientific
Review Officer, Research Programs Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, 7W602, Bethesda, MD 20892–
9750, 240–276–6456, [email protected].
Name of Committee: National Cancer
Institute Special Emphasis Panel; Planning
Grants for Global Research Infrastructure in
Non-Communicable Disease 1.
Date: October 25, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.

VerDate Sep<11>2014

18:22 Sep 22, 2016

Jkt 238001

Number of
respondents

Number of
responses per
respondent

Form name

Contact Person: Michael B. Small, Ph.D.,
Chief, Program and Review Extramural Staff
Training Office (PRESTO), Program and
Review Extramural Staff Training Office,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, 7W412, Bethesda, MD 20892–9750,
240–276–6438, [email protected].
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Omnibus SEP–1.
Date: October 27–28, 2016.
Time: 8:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
North Bethesda, MD 20852.
Contact Person: Jennifer C Schiltz, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, 7W634, Bethesda, MD 20892–
9750, 240–276–5864, jennifer.schiltz@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Quantitative Imaging for the Evaluation of
Responses to Cancer Therapies.
Date: November 2, 2016.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
2W030, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Kenneth L. Bielat, Ph.D.,
Scientific Review Officer, Research and
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, 7W244, Rockville, MD 20850, 240–
276–6373, [email protected].
Name of Committee: National Cancer
Institute Special Emphasis Panel; Research
Centers for Cancer Systems Biology
Consortium (U54).
Date: November 9–10, 2016.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, Montgomery County
Conference Center Facility, 5701 Marinelli
Road, North Bethesda, MD 20852.
Contact Person: Adriana Stoica, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,

PO 00000

Frm 00043

Fmt 4703

Sfmt 4703

Total annual
burden hours

7W234, Bethesda, MD 20892–9750, 240–276–
6368, [email protected].
Name of Committee: National Cancer
Institute Special Emphasis Panel; Member
Conflict SEP.
Date: November 10, 2016.
Time: 12:30 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W238, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Byeong-Chel Lee, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
7W238, Rockville, MD 20850, 240–276–7755,
[email protected].
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: September 19, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–22896 Filed 9–22–16; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID FEMA–2016–0022]

Revisions to the Public Assistance
Program and Policy Guide
Federal Emergency
Management Agency, DHS.
ACTION: Notice of availability; request
for comments.
AGENCY:

The Federal Emergency
Management Agency (FEMA) is
accepting comments on proposed
revisions to the Public Assistance
Program and Policy Guide (PAPPG).

SUMMARY:

E:\FR\FM\23SEN1.SGM

23SEN1